Evidence map›Paper›PMID 33471519›Full record

ArticleACS infectious diseases2021

The Discovery and Development of Thienopyrimidines as Inhibitors of

Alex K Mugengana, Nicole A Vita, Autumn Brown Gandt, Kevin Moran, George Agyapong, Lalit K Sharma, Elizabeth C Griffith, Jiuyu Liu, Lei Yang, Ekaterina Gavrish and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. RdxA-independent mechanism ofFrontiers in microbiology · 2025
    Article
  4. Opportunities forMicroorganisms · 2024
    Review
  5. Novel therapeutic regimens againstFrontiers in microbiology · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Alex K MugenganaDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, MS#1000, Memphis, Tennessee 38105, United States.
Nicole A VitaDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, MS#1000, Memphis, Tennessee 38105, United States.
Autumn Brown GandtArietis Pharma, Boston, Massachusetts 02118, United States.
Kevin MoranArietis Pharma, Boston, Massachusetts 02118, United States.
George AgyapongArietis Pharma, Boston, Massachusetts 02118, United States.
Lalit K SharmaDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, MS#1000, Memphis, Tennessee 38105, United States.
Elizabeth C GriffithDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, MS#1000, Memphis, Tennessee 38105, United States.
Jiuyu LiuDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, MS#1000, Memphis, Tennessee 38105, United States.
Lei YangDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, MS#1000, Memphis, Tennessee 38105, United States.
Ekaterina GavrishArietis Pharma, Boston, Massachusetts 02118, United States.
Kirk E HevenerDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID 0000-0002-5584-3625
Michael D LaFleurArietis Pharma, Boston, Massachusetts 02118, United States.
Richard E LeeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, MS#1000, Memphis, Tennessee 38105, United States.ORCID 0000-0002-2397-0443
St. Jude Children's Research Hospital · USArietis (United States) · USUniversity of Tennessee Health Science Center · US

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Bactericidal antibiotic for Vancomycin Resistant EnterococciR44AI122426 · NIAID · ARIETIS · PI LAFLEUR, MICHAEL · 2016 to 2018
$3.7M
Narrow-spectrum Agents Acting against Helicobacter pyloriR44AI102452 · NIAID · ARIETIS · PI COLEMAN, KENNETH · 2012 to 2015
$3.3M
NIAID NIH HHS R44 AI102452NIAID NIH HHS R44 AI122426NIGMS NIH HHS P41 GM103311
6 · The paper itself

Abstract

The successful treatment of

Indexed as

Helicobacter InfectionsHelicobacter pyloriAnimalsAnti-Bacterial AgentsElectron Transport Complex IMicePyrimidinesAnti-Bacterial AgentsElectron Transport Complex IPyrimidinesthienopyrimidinecomplex I inhibitorHelicobacter pyloriNuoDthienopyridine

Identifiers

PMID33471519
PMCPMC8122083
OpenAlexW3121696396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.